Little did I realize a few grapes could send my blood sugar soaring until I tried the first glucose monitor without a ...

San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing just under ...

The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be SAN DIEGO, June 20 ...

Medical device specialist DexCom (NASDAQ: DXCM) is going through a rough patch. The company's shares dropped off a cliff following its second-quarter earnings report. However, zooming out helps ...

After getting the green light from the FDA back in March, Dexcom today launched its first over-the-counter wearable continuous glucose biosensor, Stelo, in the U.S. market. The device is now ...

As such, Dexcom is taking a multi-pronged approach to marketing and advertising the new product, making it available for purchase directly on the company’s website and supporting it with a full media ...

Links to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com and will be archived there for future reference. About DexCom, Inc. DexCom, Inc. empowers ...

DexCom Inc (DXCM) stock saw a decline, ending the day at $68.94 which represents a decrease of $-1.15 or -1.64% from the prior close of $70.09. The stock opened at $69.99 and touched a low of $68.59 ...

The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Southern District ...